Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
Xiuning Le, MD, PhD, discusses the future of tepotinib in the treatment of NSCLC. Dr Le is an author of a phase 2 study on tepotinib, a highly selective MET inhibitor.
Radiation-enhancing particles appear to be a promising tool for improving results with radiotherapy — perhaps even across various cancers.
Over the past decade, researchers have found inconsistent evidence about whether radioactive iodine treatment for hyperthyroidism can cause cancer in the long term.
It is still unknown whether liquid biopsies are a reliable mechanism for determining disease prognosis outside of prostate cancer.
One potentially revolutionary hypothesis relates to the evolutionary processes involved in oncogenesis.
Patients with diabetes, hypercholesterolemia, or CAD had 23.9%, 11.4%, and 19.2% increased costs, respectively, versus those without risk factors for CVD.
The authors found that BRCA1-positive patients who became pregnant had improved disease-free survival, although there was no improvement in overall survival.
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results.
Secondary end points were not significantly different between the 2 groups, including overall survival.
